Dr. Robert Laprairie Neuroscience Cluster Associate Member Assistant Professor and CIHR-GlaxoSmithKline Chair in Drug Discovery and Development
Dr. Laprairie’s molecular pharmacology laboratory is focused on the discovery and development of drugs targeting the cannabinoid receptors - the same receptors that are activated by ∆9-tetrahydrocannabinol (THC) from Cannabis. These cannabinoid drugs are derived from synthetic and natural sources and may be useful for the treatment of pain, anxiety, epilepsy, and movement disorders.